Collaborations
Sharing Knowledge. Sharing Hope.
CIBMTR collaborates with the global scientific community to improve outcomes in cellular therapy. Centers from around the globe share their data with CIBMTR, and CIBMTR is committed to sharing the information and knowledge produced from those data. By building strategic partnerships, CIBMTR leverages its strengths to achieve its vision to be the premier research organization for cellular therapy.
Please click on the quick links below to access specific sections of the page.
Stem Cell Therapeutic Outcomes Database (SCTOD)
CIBMTR administers the SCTOD contract for the Health Resources and Services Administration (HRSA)-sponsored C.W. Bill Young Cell Transplantation Program (CWBYCTP). For the SCTOD, CIBMTR tracks and analyzes data for all allogeneic transplants performed in the US and transplants performed globally with products from the US.
Center-Specific Volumes and Survival Analysis
CIBMTR provides HRSA with the annual volume of transplants performed at each center, which is posted on the CWBYCTP website. CIBMTR also performs a center-specific survival analysis evaluating one-year survival rates among US centers for transplants from related and unrelated donors.
Center Outcomes Forums
CIBMTR has conducted Center Outcomes Forums to engage relevant stakeholders in the center-specific outcomes reporting process.
For more information about the SCTOD, visit the SCTOD page.
Medicare Coverage with Evidence Development (CED) Studies
Many US patients with specific diseases and / or at certain ages are denied access to cellular therapy due to lack of insurance coverage by the Centers for Medicare & Medicaid Services (CMS). CMS CED studies allow CMS to provide coverage to patients enrolled in clinical studies that inform policy decisions. CIBMTR is currently facilitating 3 CMS CED studies, and more than 10,000 patients received transplants with CMS reimbursement because of these studies.
For more information about the CMS CED studies CIBMTR facilitates, visit the Medicare CED Studies page.
Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
CIBMTR manages the BMT CTN Data and Coordinating Center with NMDP and The Emmes Company, a contract research organization. The BMT CTN conducts multicenter Phase II and III trials with broad national participation to improve outcomes of cellular therapy. For more information, visit the BMT CTN page.
Sickle Cell Disease Initiatives
Cure Sickle Cell Support. Launched in 2018 by the National Heart, Lung, and Blood Institute, the Cure Sickle Cell Initiative builds a community of patients, advocates, researchers, and scientists to accelerate promising genetic therapies to cure sickle cell disease.
- Data Consortium. Since 2019, CIBMTR has worked with the Cure Sickle Cell Data Consortium to build a research data ecosystem designed to support investigator-initiated collaborative research. US hematopoietic cell transplantation (HCT) data received by CIBMTR for sickle cell disease are now available in the National Center for Biotechnology Information database of genotypes and phenotypes for public use.
- Long-Term Follow-Up. Awarded by the National Institutes of Health (NIH) in 2024, this initiative supports planning for a long-term follow-up program for patients with sickle cell disease who are treated with either HCT or gene therapy on NIH-funded clinical trials.
CMS Innovation Center. Another initiative, funded by a supplement to CIBMTR’s NIH U24 resource grant, coordinates with the Centers for Medicare and Medicaid Services (CMS) Innovation Center to share CIBMTR clinical and patient-reported outcomes data to support a CMS Cell and Gene Therapy Access Model for Medicaid-eligible patients who receive gene therapy for sickle cell disease.
International Initiatives
CIBMTR continues to strengthen its collaborations with centers around the world as well as national and international registries. A major focus is enhancing data alignment and exchange, particularly through the harmonization of data collection. CIBMTR investigators also partner on research studies, and CIBMTR staff members mentor and train colleagues across the globe.
Industry Collaboration
CIBMTR works with industry collaborators to develop retrospective and prospective research studies. Leveraging CIBMTR’s expertise in transplantation, CAR-T, and gene therapy, CIBMTR’s team specializes in registry data and real-world evidence, research planning and support, and clinical trial management.
For more information, visit the Industry Collaborators page.
Tandem Meetings
Held annually in February, the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR is a multidisciplinary event highlighting the latest research and breakthroughs in the evolving field of HCT, cellular therapy and gene therapy.
For more information about the Tandem Meetings, visit the Tandem Meetings page.